Figure 2.

Overall survival curves for the 107 hepatocellular carcinoma (HCC) patients stratified into those with glypican (GPC)‐3‐positive and GPC3‐negative HCC. (a) Overall survival of patients with GPC3‐positive HCC was shorter than those with GPC3‐negative HCC (P = 0.031). (b) Overall survival curves in 80 of 107 HCC patients with initial treatment who underwent hepatectomy with positive and negative GPC3 expression. Patients with GPC3‐positive HCC had a lower 5‐year survival than those with GPC3‐negative HCC (P = 0.011). (c) Overall survival curves in the 71 HCC patients with initial hepatectomy who exhibited well‐ and moderately and poorly differentiated HCC on histopathological examination. The 5‐year survival rate was lower in the moderately and poorly differentiated GPC3‐positive HCC than in the corresponding GPC3‐negative HCC (P = 0.036). (d) Overall survival curves in the 71 initial treatment patients who underwent hepatectomy and exhibited moderately and poorly differentiated HCC on pathological examination with positive and negative GPC3 expression. The 5‐year survival rate was lower in the GPC3‐positive HCC patients than in the GPC3‐negative HCC patients (P = 0.035).